vs
Side-by-side financial comparison of ACADIA REALTY TRUST (AKR) and Amphastar Pharmaceuticals, Inc. (AMPH). Click either name above to swap in a different company.
Amphastar Pharmaceuticals, Inc. is the larger business by last-quarter revenue ($183.1M vs $103.0M, roughly 1.8× ACADIA REALTY TRUST). ACADIA REALTY TRUST runs the higher net margin — 135.1% vs 13.3%, a 121.7% gap on every dollar of revenue. On growth, ACADIA REALTY TRUST posted the faster year-over-year revenue change (-1.3% vs -1.8%). Over the past eight quarters, ACADIA REALTY TRUST's revenue compounded faster (7.0% CAGR vs 3.2%).
Acadia Realty Trust is a publicly traded real estate investment trust (REIT) that specializes in owning, operating, and redeveloping high-quality retail and mixed-use properties, primarily in dense, high-barrier-to-entry U.S. markets. Its portfolio includes neighborhood shopping centers, urban street retail assets, and community-focused mixed-use developments.
Amphastar Pharmaceuticals is a publicly traded American speciality pharmaceutical company. It was incorporated in May 2004 and primarily develops, manufactures, and sells inhalation and intranasal products.
AKR vs AMPH — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $103.0M | $183.1M |
| Net Profit | $139.1M | $24.4M |
| Gross Margin | — | 46.8% |
| Operating Margin | 153.9% | 19.4% |
| Net Margin | 135.1% | 13.3% |
| Revenue YoY | -1.3% | -1.8% |
| Net Profit YoY | -58.2% | -35.7% |
| EPS (diluted) | — | $0.51 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $103.0M | — | ||
| Q4 25 | — | $183.1M | ||
| Q3 25 | — | $191.8M | ||
| Q2 25 | — | $174.4M | ||
| Q1 25 | — | $170.5M | ||
| Q4 24 | $93.3M | $186.5M | ||
| Q3 24 | $87.7M | $191.2M | ||
| Q2 24 | $87.3M | $182.4M |
| Q1 26 | $139.1M | — | ||
| Q4 25 | — | $24.4M | ||
| Q3 25 | — | $17.4M | ||
| Q2 25 | — | $31.0M | ||
| Q1 25 | — | $25.3M | ||
| Q4 24 | $1.2M | $38.0M | ||
| Q3 24 | $12.3M | $40.4M | ||
| Q2 24 | $1.6M | $37.9M |
| Q1 26 | — | — | ||
| Q4 25 | — | 46.8% | ||
| Q3 25 | — | 51.4% | ||
| Q2 25 | — | 49.6% | ||
| Q1 25 | — | 50.0% | ||
| Q4 24 | — | 46.5% | ||
| Q3 24 | — | 53.3% | ||
| Q2 24 | — | 52.2% |
| Q1 26 | 153.9% | — | ||
| Q4 25 | — | 19.4% | ||
| Q3 25 | — | 13.2% | ||
| Q2 25 | — | 24.2% | ||
| Q1 25 | — | 21.9% | ||
| Q4 24 | 17.5% | 24.2% | ||
| Q3 24 | 19.9% | 29.8% | ||
| Q2 24 | 20.4% | 30.3% |
| Q1 26 | 135.1% | — | ||
| Q4 25 | — | 13.3% | ||
| Q3 25 | — | 9.0% | ||
| Q2 25 | — | 17.8% | ||
| Q1 25 | — | 14.8% | ||
| Q4 24 | 1.2% | 20.4% | ||
| Q3 24 | 14.0% | 21.1% | ||
| Q2 24 | 1.8% | 20.8% |
| Q1 26 | — | — | ||
| Q4 25 | — | $0.51 | ||
| Q3 25 | — | $0.37 | ||
| Q2 25 | — | $0.64 | ||
| Q1 25 | — | $0.51 | ||
| Q4 24 | $0.08 | $0.74 | ||
| Q3 24 | $0.07 | $0.78 | ||
| Q2 24 | $0.01 | $0.73 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $31.4M | $282.8M |
| Total DebtLower is stronger | — | $608.7M |
| Stockholders' EquityBook value | $2.6B | $788.8M |
| Total Assets | $4.5B | $1.6B |
| Debt / EquityLower = less leverage | — | 0.77× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $31.4M | — | ||
| Q4 25 | — | $282.8M | ||
| Q3 25 | — | $276.2M | ||
| Q2 25 | — | $231.8M | ||
| Q1 25 | — | $236.9M | ||
| Q4 24 | $16.8M | $221.6M | ||
| Q3 24 | $46.2M | $250.5M | ||
| Q2 24 | $31.9M | $217.8M |
| Q1 26 | — | — | ||
| Q4 25 | — | $608.7M | ||
| Q3 25 | — | $608.6M | ||
| Q2 25 | — | $607.7M | ||
| Q1 25 | — | $603.9M | ||
| Q4 24 | $1.5B | $601.6M | ||
| Q3 24 | $1.6B | $596.4M | ||
| Q2 24 | $1.7B | $586.9M |
| Q1 26 | $2.6B | — | ||
| Q4 25 | — | $788.8M | ||
| Q3 25 | — | $776.7M | ||
| Q2 25 | — | $757.5M | ||
| Q1 25 | — | $751.3M | ||
| Q4 24 | $2.1B | $732.3M | ||
| Q3 24 | $1.9B | $727.7M | ||
| Q2 24 | $1.8B | $713.3M |
| Q1 26 | $4.5B | — | ||
| Q4 25 | — | $1.6B | ||
| Q3 25 | — | $1.7B | ||
| Q2 25 | — | $1.6B | ||
| Q1 25 | — | $1.6B | ||
| Q4 24 | $4.4B | $1.6B | ||
| Q3 24 | $4.3B | $1.5B | ||
| Q2 24 | $4.3B | $1.5B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.77× | ||
| Q3 25 | — | 0.78× | ||
| Q2 25 | — | 0.80× | ||
| Q1 25 | — | 0.80× | ||
| Q4 24 | 0.74× | 0.82× | ||
| Q3 24 | 0.82× | 0.82× | ||
| Q2 24 | 0.95× | 0.82× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $32.9M |
| Free Cash FlowOCF − Capex | — | $24.6M |
| FCF MarginFCF / Revenue | — | 13.4% |
| Capex IntensityCapex / Revenue | 1.7% | 4.5% |
| Cash ConversionOCF / Net Profit | — | 1.35× |
| TTM Free Cash FlowTrailing 4 quarters | — | $121.2M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | — | $32.9M | ||
| Q3 25 | — | $52.6M | ||
| Q2 25 | — | $35.6M | ||
| Q1 25 | — | $35.1M | ||
| Q4 24 | $140.4M | $29.0M | ||
| Q3 24 | $44.6M | $60.0M | ||
| Q2 24 | $32.0M | $69.1M |
| Q1 26 | — | — | ||
| Q4 25 | — | $24.6M | ||
| Q3 25 | — | $47.2M | ||
| Q2 25 | — | $25.0M | ||
| Q1 25 | — | $24.4M | ||
| Q4 24 | — | $16.6M | ||
| Q3 24 | — | $46.2M | ||
| Q2 24 | — | $63.1M |
| Q1 26 | — | — | ||
| Q4 25 | — | 13.4% | ||
| Q3 25 | — | 24.6% | ||
| Q2 25 | — | 14.3% | ||
| Q1 25 | — | 14.3% | ||
| Q4 24 | — | 8.9% | ||
| Q3 24 | — | 24.1% | ||
| Q2 24 | — | 34.6% |
| Q1 26 | 1.7% | — | ||
| Q4 25 | — | 4.5% | ||
| Q3 25 | — | 2.8% | ||
| Q2 25 | — | 6.1% | ||
| Q1 25 | — | 6.3% | ||
| Q4 24 | — | 6.7% | ||
| Q3 24 | — | 7.2% | ||
| Q2 24 | — | 3.3% |
| Q1 26 | — | — | ||
| Q4 25 | — | 1.35× | ||
| Q3 25 | — | 3.03× | ||
| Q2 25 | — | 1.15× | ||
| Q1 25 | — | 1.39× | ||
| Q4 24 | 121.08× | 0.76× | ||
| Q3 24 | 3.64× | 1.48× | ||
| Q2 24 | 20.25× | 1.82× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AKR
| Rental | $98.6M | 96% |
| Other | $4.4M | 4% |
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
